SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Redeye Says Larger Cohort Confirms BioInvent BI-1808 Efficacy

Redeye’s analyst says a larger cohort confirms efficacy for BioInvent’s BI-1808.

Related stories